Report in English with a Dutch summary (KCE reports 45A)
Report in English with a Dutch summary (KCE reports 45A) Report in English with a Dutch summary (KCE reports 45A)
128 Screening for Colorectal Cancer: Appendices KCE reports vol.45 7.2.2 Groups at increased or high risk High risk groups represent approximately 15 % of colorectal cancer cases in the Netherlands. Periodic surveillance colonoscopies are being performed in people at increased or high risk: Carriers of genetic mutations such as Hereditary NonPolyposis Colon Cancer (HNPCC) and Familial Adenomatous Polyposis (FAP) Family risk of colorectal cancer Individuals suffering from diseases that are linked to an increased risk for colorectal cancer (personal history of CRC, Crohn and Colitis Ulcerosa) There s a registry-guided surveillance program used by the Dutch Hereditary Colorectal Cancer Registry. Personal and family data, pathology reports, and treatment outcomes are collected for this registry. The family physician is responsible for maintaining surveillance among the family members. STOET 526 aims at the prevention of hereditary cancer tumours. Families at risk for hereditary cancer have to be referred to a Polikliniek Erfelijke Tumoren by the GP or a specialist. If their risk status has been confirmed by a geneticist this can be registered at STOET. If family history shows that a person is at high risk, he/she will be advised to get examined annually or every two years, and for individuals older than 60 every five years. Mostly examinations will start between the age of 20 and 25. The relative at risk will be referred by the GP to get a policlinical consultation with a gastroenterologist, an internist or a surgeon. In a first consultation the advisability of regular preventive examinations will be discussed. The periodic examination could be either colonoscopy, or sigmoidoscopy combined with a double contrast barium enema. 7.3 FINLAND 7.3.1 Average risk groups In Finland, the Ministry of Social Affairs and Health made a recommendation in 2003 to the municipalities to run a randomized feasibility study with FOBT (unrehydrated Hemoccult II) screening for colorectal cancer as a public health policy that is repeated every second year 527. Health care in Finland is decentralised, organised by municipal authorities. It is up to them to decide whether to start colorectal cancer screening. The municipals also pay the actual screening costs. The organisational costs are centrally paid. For the first six years of introduction, each age cohort is randomized to screening or the usual care (no screening) at the age of 60-64 years. The program is a centralized public health policy with gradual or stepped initial phase covering 15% of the municipal specific population in the first year and 50% in the sixth year. In 2004 the first 23 municipalities started with more than 5.000 screened individuals in a target population of 35.000. The individuals are selected by random sampling from the population register for invitees and controls by municipality and by birthcohort. The ultimate target population is approximately 500.000 individuals at 60-/69 years of age. Screening is being gradually expanded to cover this whole age group. Initially it has focused specifically on 60, 62 and 64 year-olds. The non-invited controls will gradually
KCE reports vol.45 Screening for Colorectal Cancer: Appendices 129 be screened only after the six-year implementation period. The effects of screening will be evaluated, comparing the incidence of CRC and the mortality from CRC in those invited to screening with controls. In that way the implementation of colorectal cancer screening in Finland meets the criteria for a randomized controlled trial and the requirements for a public health program. This provided an opportunity to evaluate the program after five years and to further adjust the screening strategy or to implement FOBT. The screening program uses FOBT (unrehydrated Hemoccult II), a sample collection procedure performed on three consecutive days. People in the target group receive and return the tests by post. A Colorectal Screening Centre based in the city of Tampere handles the distribution of FOBT s, interpretation of results and contact with people tested. It provides advice and guidance for people whose test results reveal the presence of blood in their stool samples to ensure they undergo further testing arranged by their local health centre. The tests are free of charge for the people being screened. The cost of screening is estimated at 8 euro per invitation including the test and mail charges, analysing the tests and providing the participants with written test results and possible referrals for further examinations. In 2004, 4539 were invited for screening; 75 % participated. 7.3.2 Groups at increased or high risk Nation-wide preventative colonoscopic surveillance for mutation carriers in HNPCC families has been organized since the early 80 s by the Finnish HNPCC registry 528. 7.4 GERMANY 7.4.1 Average risk groups In Germany there s no national screening program but different screening options are being offered and paid by the statutory health insurance529, 530: Annual FOBT test for individuals from 50 to 54 years old Colonoscopy every 10 years from the age of 55 (since october 2002) If the individual does not opt for a colonoscopy, the statutory health insurance will refund FOBT every two years from the age of 55. In 2003, 500.000 patients underwent colonoscopy screening 531. All examinations are documented. A central institution collects the completed data sheets, and an electronic version of the standardised colonoscopy protocol is being prepared.
- Page 88 and 89: 78 Screening for Colorectal Cancer
- Page 90 and 91: 80 Screening for Colorectal Cancer
- Page 92 and 93: 82 Screening for Colorectal Cancer
- Page 94 and 95: 84 Screening for Colorectal Cancer
- Page 96 and 97: 86 Screening for Colorectal Cancer
- Page 98 and 99: 88 Screening for Colorectal Cancer
- Page 100 and 101: 90 Screening for Colorectal Cancer
- Page 102 and 103: 92 Screening for Colorectal Cancer
- Page 104 and 105: 94 Screening for Colorectal Cancer
- Page 106 and 107: 96 Screening for Colorectal Cancer
- Page 108 and 109: 98 Screening for Colorectal Cancer
- Page 110 and 111: 100 Screening for Colorectal Cancer
- Page 112 and 113: 102 Screening for Colorectal Cancer
- Page 114 and 115: 104 Screening for Colorectal Cancer
- Page 116 and 117: 106 Screening for Colorectal Cancer
- Page 118 and 119: 108 Screening for Colorectal Cancer
- Page 120 and 121: 110 Screening for Colorectal Cancer
- Page 122 and 123: 112 Screening for Colorectal Cancer
- Page 124 and 125: 114 Screening for Colorectal Cancer
- Page 126 and 127: 116 Screening for Colorectal Cancer
- Page 128 and 129: 118 Screening for Colorectal Cancer
- Page 130 and 131: 120 Screening for Colorectal Cancer
- Page 132 and 133: 122 Screening for Colorectal Cancer
- Page 134 and 135: 124 Screening for Colorectal Cancer
- Page 136 and 137: 126 Screening for Colorectal Cancer
- Page 140 and 141: 130 Screening for Colorectal Cancer
- Page 142 and 143: 132 Screening for Colorectal Cancer
- Page 144 and 145: 134 Screening for Colorectal Cancer
- Page 146 and 147: 136 Screening for Colorectal Cancer
- Page 148 and 149: 138 Screening for Colorectal Cancer
- Page 150 and 151: 140 Screening for Colorectal Cancer
- Page 152 and 153: 142 Screening for Colorectal Cancer
- Page 154 and 155: 144 Screening for Colorectal Cancer
- Page 156 and 157: 146 Screening for Colorectal Cancer
- Page 158 and 159: 148 Screening for Colorectal Cancer
- Page 160 and 161: 150 Screening for Colorectal Cancer
- Page 162 and 163: 152 Screening for Colorectal Cancer
- Page 164 and 165: 154 Screening for Colorectal Cancer
- Page 166 and 167: 156 Screening for Colorectal Cancer
- Page 168 and 169: 158 Screening for Colorectal Cancer
- Page 170 and 171: 160 Screening for Colorectal Cancer
- Page 172 and 173: 162 Screening for Colorectal Cancer
- Page 174 and 175: 164 Screening for Colorectal Cancer
- Page 176 and 177: 166 Screening for Colorectal Cancer
- Page 178 and 179: 168 Screening for Colorectal Cancer
- Page 180 and 181: 170 Screening for Colorectal Cancer
- Page 182 and 183: 172 Screening for Colorectal Cancer
- Page 184 and 185: 174 Screening for Colorectal Cancer
- Page 186 and 187: 176 Screening for Colorectal Cancer
<strong>KCE</strong> <strong>reports</strong> vol.45 Screen<strong>in</strong>g for Colorectal Cancer: Appendices 129<br />
be screened only after the six-year implementation period. The effects of<br />
screen<strong>in</strong>g will be evaluated, compar<strong>in</strong>g the <strong>in</strong>cidence of CRC and the mortality<br />
from CRC <strong>in</strong> those <strong>in</strong>vited to screen<strong>in</strong>g <strong>with</strong> controls. In that way the<br />
implementation of colorectal cancer screen<strong>in</strong>g <strong>in</strong> F<strong>in</strong>land meets the criteria for a<br />
randomized controlled trial and the requirements for a public health program.<br />
This provided an opportunity to evaluate the program after five years and to<br />
further adjust the screen<strong>in</strong>g strategy or to implement FOBT.<br />
The screen<strong>in</strong>g program uses FOBT (unrehydrated Hemoccult II), a sample<br />
collection procedure performed on three consecutive days. People <strong>in</strong> the target<br />
group receive and return the tests by post. A Colorectal Screen<strong>in</strong>g Centre<br />
based <strong>in</strong> the city of Tampere handles the distribution of FOBT s, <strong>in</strong>terpretation<br />
of results and contact <strong>with</strong> people tested. It provides advice and guidance for<br />
people whose test results reveal the presence of blood <strong>in</strong> their stool samples to<br />
ensure they undergo further test<strong>in</strong>g arranged by their local health centre.<br />
The tests are free of charge for the people be<strong>in</strong>g screened. The cost of<br />
screen<strong>in</strong>g is estimated at 8 euro per <strong>in</strong>vitation <strong>in</strong>clud<strong>in</strong>g the test and mail<br />
charges, analys<strong>in</strong>g the tests and provid<strong>in</strong>g the participants <strong>with</strong> written test<br />
results and possible referrals for further exam<strong>in</strong>ations. In 2004, 4539 were<br />
<strong>in</strong>vited for screen<strong>in</strong>g; 75 % participated.<br />
7.3.2 Groups at <strong>in</strong>creased or high risk<br />
Nation-wide preventative colonoscopic surveillance for mutation carriers <strong>in</strong><br />
HNPCC families has been organized s<strong>in</strong>ce the early 80 s by the F<strong>in</strong>nish HNPCC<br />
registry 528.<br />
7.4 GERMANY<br />
7.4.1 Average risk groups<br />
In Germany there s no national screen<strong>in</strong>g program but different screen<strong>in</strong>g<br />
options are be<strong>in</strong>g offered and paid by the statutory health <strong>in</strong>surance529, 530:<br />
Annual FOBT test for <strong>in</strong>dividuals from 50 to 54 years old<br />
Colonoscopy every 10 years from the age of 55 (s<strong>in</strong>ce october<br />
2002)<br />
If the <strong>in</strong>dividual does not opt for a colonoscopy, the statutory health <strong>in</strong>surance<br />
will refund FOBT every two years from the age of 55.<br />
In 2003, 500.000 patients underwent colonoscopy screen<strong>in</strong>g 531.<br />
All exam<strong>in</strong>ations are documented. A central <strong>in</strong>stitution collects the completed<br />
data sheets, and an electronic version of the standardised colonoscopy protocol<br />
is be<strong>in</strong>g prepared.